177 related articles for article (PubMed ID: 32847130)
41. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
42. HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs.
Zeng H; Wang W; Zhang L; Lin Z
Cancer Drug Resist; 2024; 7():14. PubMed ID: 38835349
[TBL] [Abstract][Full Text] [Related]
43. Novel agents that downregulate EGFR, HER2, and HER3 in parallel.
Ferreira RB; Law ME; Jahn SC; Davis BJ; Heldermon CD; Reinhard M; Castellano RK; Law BK
Oncotarget; 2015 Apr; 6(12):10445-59. PubMed ID: 25865227
[TBL] [Abstract][Full Text] [Related]
44. The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.
Trinder A; Ding K; Zhang J
Curr Med Chem; 2024 Jan; ():. PubMed ID: 38231075
[TBL] [Abstract][Full Text] [Related]
45. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
[TBL] [Abstract][Full Text] [Related]
46. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
47. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.
Tricker EM; Xu C; Uddin S; Capelletti M; Ercan D; Ogino A; Pratilas CA; Rosen N; Gray NS; Wong KK; Jänne PA
Cancer Discov; 2015 Sep; 5(9):960-971. PubMed ID: 26036643
[TBL] [Abstract][Full Text] [Related]
48. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
[TBL] [Abstract][Full Text] [Related]
49. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
Campbell MR; Amin D; Moasser MM
Clin Cancer Res; 2010 Mar; 16(5):1373-83. PubMed ID: 20179223
[TBL] [Abstract][Full Text] [Related]
50. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance.
Uribe ML; Marrocco I; Yarden Y
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206026
[TBL] [Abstract][Full Text] [Related]
51. HER3 Alterations in Cancer and Potential Clinical Implications.
Kilroy MK; Park S; Feroz W; Patel H; Mishra R; Alanazi S; Garrett JT
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551663
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm.
Cai W; Ratnayake R; Wang M; Chen QY; Raisch KP; Dang LH; Law BK; Luesch H
Curr Res Pharmacol Drug Discov; 2021; 2():100053. PubMed ID: 34909679
[TBL] [Abstract][Full Text] [Related]
53. Systematic omics analysis identifies CCR6 as a therapeutic target to overcome cancer resistance to EGFR inhibitors.
Kwon EJ; Cha HJ; Lee H
iScience; 2024 Apr; 27(4):109448. PubMed ID: 38551001
[TBL] [Abstract][Full Text] [Related]
54. Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
Reyes A; Pharaon R; Mohanty A; Massarelli E
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370772
[TBL] [Abstract][Full Text] [Related]
55. Long road towards effective HER3 targeting in breast cancer.
Papa F; Grinda T; Rassy E; Cheickh-Hussin R; Ribeiro J; Antonuzzo L; Pistilli B
Cancer Treat Rev; 2024 Jun; 129():102786. PubMed ID: 38885540
[TBL] [Abstract][Full Text] [Related]
56. Targeting the evolution of drug resistance in lung cancer.
Shah KN; Bandyopadhyay S
Mol Cell Oncol; 2019; 6(5):e1603092. PubMed ID: 31528688
[TBL] [Abstract][Full Text] [Related]
57. Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Cancer Discov; 2022 Jun; 12(6):1598. PubMed ID: 35652222
[No Abstract] [Full Text] [Related]
58. Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3.
PLOS ONE Editors
PLoS One; 2022; 17(4):e0267745. PubMed ID: 35468166
[No Abstract] [Full Text] [Related]
59. Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor.
Fujino T; Mitsudomi T
JTO Clin Res Rep; 2021 Mar; 2(3):100134. PubMed ID: 34589997
[No Abstract] [Full Text] [Related]
60. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.
Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB
Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
